

# CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.  
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.02.2018

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai -400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.02.2018

Ref: Our Company's letters dated 13.02.2018 and 31.01.2018

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Concord Drugs Limited held on Wednesday, 14.02.2018 at 5.30 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayathnagar Mandal - 501511, Telangana the following were considered and approved:

1. Un-audited financial results for the quarter ended 31.12.2017. (Attached)
2. Limited Review Report for the quarter ended 31.12.2017. (Attached)

The meeting concluded at 6.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.


Yours faithfully,  
For Concord Drugs Limited

*S. Koni Reddy*

S. Koni Reddy  
Whole-time Director & CFO  
DIN: 02829319



Encl: as above



# CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.  
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in


CONCORD DRUGS LIMITED							
Statement of Un-Audited Results for the Quarter ended 31.12.2017							
S.No.	Particulars	Quarter Ended			Nine months Ended		Year Ended
		31.12.2017 Un-Audited	30.09.2017 Un-Audited	31.12.2016 Un-Audited	31.12.2017 Un-Audited	31.12.2016 Un-Audited	31.03.2017 Audited
I.	Revenue from Operations	596.12	376.71	921.45	3,070.17	3,605.89	5,748.97
II.	Other Income	1.21	-	2.31	2.19	5.85	8.57
III.	Total income (I+II)	597.33	376.71	923.76	3,072.36	3,611.74	5,757.54
IV.	Expenses						
	(a) Cost of Materials consumed	262.15	163.25	733.44	2,629.71	2,942.70	4,650.89
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and	(45.07)	(41.37)	(279.74)	(433.71)	(348.38)	(40.38)
	(d) Employee benefits expense	74.19	83.79	64.91	213.58	176.24	280.65
	(e) Finance Cost	43.41	30.03	52.71	131.24	164.71	235.99
	(f) Depreciation and amortisation expense	59.67	57.32	64.21	171.96	186.67	258.40
	(h) Other expenses	152.13	75.26	96.65	294.25	210.77	307.24
	Total Expenses	546.48	368.28	732.18	3,007.03	3,332.71	5,692.79
V.	Profit / (Loss) before and exceptional items and Tax ( III-IV)	50.85	8.43	191.58	65.32	279.03	64.75
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	50.85	8.43	191.58	65.32	279.03	64.75
VIII.	Tax expense	-	-	-	-	-	-
	Current Tax	15.22	2.53	59.20	19.60	85.43	35.72
	Deferred Tax	-	-	-	-	-	9.42
IX.	Net Profit / (Loss) after Tax (VII-VIII)	35.63	5.90	132.38	45.73	193.60	19.61
X.	Other Comprehensive Income	-	-	-	-	-	-
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XI.	Total Comprehensive Income	35.63	5.90	132.38	45.73	193.60	19.61
XII.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	786.18	724.80	724.80	786.18	724.80	724.80
XIII.	Earnings Per Equity Share of face value of Rs.10/- each)	-	-	-	-	-	-
	a) Basic ( In Rs.)	0.45	0.08	1.83	0.58	2.67	0.27
	a) Diluted ( In Rs.)	0.41	0.08	1.83	0.52	2.67	0.27

Date: 14-02-18  
Place: Hyderabad

For CONCORD DRUGS LIMITED

*S. Koni Reddy*  
Koni Reddy Seelan  
Whole-time director & CFO  
DIN:02829319





# CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.  
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

## NOTES:

- 1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.02.2018
- 2 The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Standardlone Financial results for the corresponding quarter ended December 31, 2016 have been stated in terms of SEBI Circular dated July, 05, 2016.
- 3 Reconciliation of results between previously reported ( referred to as "Previous GAAP") and Ind-AS for the corresponding quarter and Nine months ended 31 December, 2016 is as under:

Particulars	Quarter ended 31st Dec, 2016	Nine months ended 31-12- 2016
Net Profit/(Loss) after Tax under Indian GAAP	132.38	193.60
Details of Ind-As Adjustments		
Impairment of Fixed Assets	-	-
Other	-	-
Net Profit for the period as per Ind-AS	132.38	193.60
Add: Other Comprehensive Income	-	-
Total Comprehensive Income for the Period as per Ind-AS	132.38	193.60

- 4 During the quarter the Company has allotted 15,00,000 warrants to the promoters and others on preferential basis. Out of which 6,18,000 warrants have been converted into 6,18,000 equity shares.
- 5 The results are also available on the website of the Company [www.concorddrugs.in](http://www.concorddrugs.in)
- 6 The Company is engaged in "Manufacturing of Pharmaceuticals" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

Station: Hyderabad  
Date : 14.02.2018

For CONCORD DRUGS LIMITED

*S. Koni Reddy*

Koni Reddy Seelam  
Whole-time director & CFO  
DIN:02829319





**LIMITED REVIEW REPORT**

To,  
**The Board of Directors,**  
**CONCORD DRUGS LIMITED**

We have reviewed the accompanying statement of Un-audited Financial Results of **CONCORD DRUGS LIMITED** for the quarter ended and nine months ended **31<sup>st</sup> December, 2017** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ( "Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date:14<sup>th</sup>February, 2018

For M M REDDY & CO.,  
Chartered Accountants  
Chartered Accountants  
M. Madhusudhana Reddy  
Partner  
Membership No. 213077